Nyxoah医疗技术公司EPS对2024财政年度的预测由分析师降低,目标价格调整。 Medical tech firm Nyxoah's EPS forecast for FY2024 lowered by analysts, target prices adjusted.
Nyxoah医疗技术公司(NYXH)的EPS预测被Cantor Fitzgerald降低到2024财政年度每股1.98美元,同时保持“超重”评级和16美元的价格目标。 Medical tech firm Nyxoah's (NYXH) EPS forecast has been lowered to ($1.98) per share for FY2024 by Cantor Fitzgerald, while maintaining an "Overweight" rating and a $16.00 price objective. 奥本海默将其目标价从15美元下调至13美元，维持“跑赢大盘”评级。 Oppenheimer cut its price target from $15 to $13, keeping an "outperform" rating. 其他分析师也发布了关于该股票的报告,Cantor Fitzgerald将其目标价格从18美元降至17美元并发布"超重"评级,Stifel Nicolaus将其目标价格从27美元降至19美元,同时保持买入评级. Other analysts have also issued reports on the stock, with Cantor Fitzgerald reducing its target price from $18 to $17 and issuing an "overweight" rating, and Stifel Nicolaus lowering its target price from $27 to $19 while maintaining a buy rating. HC Wainwright重申购买评级,并设定了18美元的价格目标。 HC Wainwright reaffirmed a buy rating and set a $18 price objective. Nyxoah的重点是睡眠失常的呼吸条件,其主要产品是Genio系统,一种中度至严重阻塞睡眠动脉的低度神经刺激疗法。 Nyxoah focuses on sleep disordered breathing conditions, with its lead product being the Genio system, a hypoglossal neurostimulation therapy for moderate to severe obstructive sleep apnea.